Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046011 | 0.90 | ALDH1A1 (0.49) | MAPTALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19030153 | 0.87 | MAPT (0.46) | IRAK4MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19030512 | 0.86 | MAPT (0.49) | IRAK4MAPTALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL19029918 | 0.86 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19030726 | 0.86 | IRAK4 (0.46) | IRAK4MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19030837 | 0.85 | IRAK4 (0.44) | IRAK4MAPTALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL19045344 | 0.85 | IRAK4 (0.38) | IRAK4MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19029877 | 0.85 | IRAK4 (0.48) | IRAK4MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19030433 | 0.85 | MAPT (0.49) | MAPTALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19030128 | 0.85 | IRAK4 (0.52) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3642199-B1 | BENZOFURANS AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-108473498-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10899774-B2 | IRAK4 modulators | GENENTECH, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3642199-A1 | BENZOFURANS AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20200115388-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200115388-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| CN-110770229-A | Benzofuran compounds as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018234343-A1 | BENZOFURANS AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| EP-3394066-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899774-B2 | IRAK4 modulators | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885MAPT 1858/4885ALDH1A1 1862/4885 |
| US-20200115388-A1 | IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885MAPT 1858/4885ALDH1A1 1862/4885 |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAPT 1916/4885ALDH1A1 1146/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAPT 2319/4885ALDH1A1 1115/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAPT 1916/4885ALDH1A1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.